jeudi 29 septembre 2016

Onco Actu du 29 septembre 2016

2. Etiologie

Tattoo ink contains cancer-causing chemicals – so why isn't it regulated? [The Guardian]

4. Dépistage, diagnostic et pronostic

High-tech scan after chemotherapy could indicate whether head and neck cancer treatment is working [The Institute of Cancer Research]

5. Traitements

Is every disease a rare disease? [STAT]

5.10 Traitements - Essais

80% of Chinese clinical trials' data fabricated [PharmaFile]

5.12 Immunothérapies

On the Horizon of Cancer: The Future of Immunotherapy [Kantar Health]

CICON16: Bacteria and Cancer Immunity [CRI]

5.12.1 Immunothérapies - partenariats

bluebird bio and Medigene Establish Strategic T Cell Receptor (TCR) Alliance in Cancer Immunotherapy [bluebird bio]

5.12.3 Immunothérapies-combinaisons

Incyte’s IDO1 update on its Keytruda combo scores some positive reviews [EndPoints]

5.2 Pharma

Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution [FiercePharma]

Why big pharma wants to collect 2 million genomes [Nature]

5.2.1 Pharma - Partenariats

Boehringer Ingelheim Boosts Immune-Oncology Pipeline through Collaboration with VitaTherapeutics [Boehringer Ingelheim]

Gearing up new partnerships, Boehringer gets an option to buy a new player in oncolytic viruses in $230M deal [EndPoints]

5.3 Traitements - FDA, EMA,...

Is the FDA Too Cozy With Drug Companies? [Time]

EU-US collaboration to boost medicine development for rare diseases [ESMO]

5.4 Traitements - Economie

Most Americans believe prescription drug prices are unreasonable [STAT]

5.6 ESMO

Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress [Clovis Oncology]

Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016 [Merck]

Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress [Pfizer]

ESMO 2016 Poster Abstracts Published Online Today [ESMO]

6. Lutte contre les cancers

NCI collaborates with Multiple Myeloma Research Foundation [NIH]

6.10 Politiques

Science spending boosted in French budget [Nature]

6.10.1 Politiques (USA)

ASCO Calls on Congress to Fund Cancer Moonshot Initiative [ASCO]

6.3 Associations/Fondations

What some stories missed about the muscular dystrophy drug approval: Pharma’s close ties to vocal patient advocacy groups [HealthNewsReview]

6.6 Publications

Old Media, New Media, Data Media: Evolving Publishing Paradigms [Scholarly Kitchen]

6.9 Controverses

Flawed Research Tool Leads To Faulty Medical Findings [NPR]

Despite the Hype Over Gene Therapy, Few Drugs Are Close to Approval [MIT Technology Review]